StockData
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. (LYEL) stock

LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.67−0.98 (-6.69%)

Close on Nov 17, 2026Market cap $334.99MP/E –Yield –

Lyell Immunopharma profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Lyell Immunopharma's profit margin for the twelve months ending Jun 30, 2026 was -920285.2%. For fiscal 2025 it was -762355.6%, against -562285.2% the year before. The highest annual figure on record is -216.2% in fiscal 2022.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-762355.6%−200070.3
FY2024Dec 31, 2024-562285.2%−381799.1
FY2023Dec 31, 2023-180486.2%−180269.9
FY2022Dec 31, 2022-216.2%+2133.2
FY2021Dec 31, 2021-2349.5%+286.8
FY2020Dec 31, 2020-2636.3%+17055.8
FY2019Dec 31, 2019-19692.1%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-1118875.0%−585325.0
Q1 FY2026Mar 31, 2026-1207650.0%−462007.1
Q4 FY2025Dec 31, 2025-2345383.3%−600519.7
Q3 FY2025Sep 30, 2025-258973.3%−127846.9
Q2 FY2025Jun 30, 2025-533550.0%−181173.1
Q1 FY2025Mar 31, 2025-745642.9%+1276590.5
Q4 FY2024Dec 31, 2024-1744863.6%−1337709.8
Q3 FY2024Sep 30, 2024-131126.5%+72285.5
Q2 FY2024Jun 30, 2024-352376.9%−115747.3
Q1 FY2024Mar 31, 2024-2022233.3%−1919219.5
Q4 FY2023Dec 31, 2023-407153.8%−407136.5
Q3 FY2023Sep 30, 2023-203412.0%+2138388.0
Q2 FY2023Jun 30, 2023-236629.6%−236528.0
Q1 FY2023Mar 31, 2023-103013.8%−90691.2
Q4 FY2022Dec 31, 2022-17.4%+2948.8
Q3 FY2022Sep 30, 2022-2341800.0%−2340026.0
Q2 FY2022Jun 30, 2022-101.6%+2280.2
Q1 FY2022Mar 31, 2022-12322.6%−10071.4
Q4 FY2021Dec 31, 2021-2966.2%−1285.5
Q3 FY2021Sep 30, 2021-1774.0%+1564.2
Q2 FY2021Jun 30, 2021-2381.8%+846.4
Q1 FY2021Mar 31, 2021-2251.2%–
Q4 FY2020Dec 31, 2020-1680.7%–
Q3 FY2020Sep 30, 2020-3338.2%–
Q2 FY2020Jun 30, 2020-3228.2%–

More Lyell Immunopharma figures

See a number that looks wrong?